BridgeBio Shares Data On Serum TTR Increase When Switching Participants From Placebo And Tafamidis To Acoramidis In ATTRibute-CM And Its Open-Label Extension; Showed A 42% Reduction In Composite CVH And ACM, And A 50% Reduction In The Cumulative...
BridgeBio Shares Data On Serum TTR Increase When Switching Participants From Placebo And Tafamidis To Acoramidis In ATTRibute-CM And Its Open-Label Extension; Showed A 42% Reduction In Composite CVH And ACM, And A 50% Reduction In The Cumulative...
BridgeBio在ATTRibute-Cm及其开放标签延伸研究中分享了将参与者从安慰剂和他法米地切换到阿科莫地斯后的血清TTR增加数据；显示出综合心血管事件和ACm的减少42%，累积死亡和心血管急性事件的减少50%。
BridgeBio Shares Data On Serum TTR Increase When Switching Participants From Placebo And Tafamidis To Acoramidis In ATTRibute-CM And Its Open-Label Extension; Showed A 42% Reduction In Composite CVH And ACM, And A 50% Reduction In The Cumulative Frequency Of CVH Events Relative To Placebo At Month 30
BridgeBio在ATTRibute-Cm及其开放标签延伸研究中分享了从安慰剂和Tafamidis切换参与者到Acoramidis时血清TTR的增加数据；在第30个月，相对于安慰剂，综合CVH和ACm减少了42％，CVH事件的累积频率降低了50％。
- In participants who switched from tafamidis and placebo in the ATTRibute-CM study to acoramidis in its open-label extension (OLE), there was a mean of 3.0mg/dL increase in serum transthyretin (TTR) at Month 1 of the OLE (n=21) and mean of 3.4mg/dL increase in serum TTR at Month 6 of the OLE (n=18)
- 在从ATTRibute-Cm研究中将Tafamidis和安慰剂切换到其开放标签延伸研究中的参与者（OLE），OLE一个月时血清转甲状腺素（TTR）平均增加3.0mg/dL（n=21），OLE六个月时血清TTR平均增加3.4mg/dL（n=18）。
- Increased...
-...
登录免费看全文
登录/注册